Document Detail

Effects of fosinopril on the blood pressure and lipid profile of patients undergoing heart transplantation.
MedLine Citation:
PMID:  9154957     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The purpose of this study was to determine whether the angiotensin-converting enzyme inhibitor, fosinopril, has an antihypertensive effect in patients undergoing heart transplantation (HT), as well as any action on lipid levels (total cholesterol and its fractions, triglycerides and lipoprotein[a] [Lp(a)]). METHODS: The study included 15 male patients aged 54 +/- 10 years; nine had undergone transplantation as a result of ischemic heart disease and six as a result of idiopathic dilated cardiomyopathy. The average time from the heart transplantation was 12 +/- 4 months. Six transplantations were performed after antidiabetic treatment, and six were performed with patients receiving a hypolipidemic agent. The subjects of the study were patients with mild to moderate hypertension who were receiving antihypertensive treatment; the antihypertensive medications were withdrawn during 7 days. Periodic blood pressure and basal analytic determinations were then carried out after 4 and 12 weeks of treatment and 7 days after withdrawal of the antihypertensive medications. RESULTS: Significant differences (p < 0.05) were found in the systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared with the basal values (SBP 160 +/- 11 mm Hg; DBP 98 +/- 8 mm Hg), after 4 weeks of treatment (SBP 138 +/- 10 mm Hg; DBP 83 +/- 7 mm Hg), and after 12 weeks of treatment (SBP 137 +/- 12 mm Hg; DBP 84 +/- 9 mm Hg); these differences persisted 7 days after the drug was withdrawn (SBP 150 +/- 12 mm Hg; DBP 95 +/- 10 mm Hg). The total cholesterol, low-density lipoprotein (LDL) cholesterol, and Lp(a) dropped compared with the basal levels (total cholesterol 184 +/- 19, LDL cholesterol 123 +/- 13, Lp(a) 29 +/- 12), after 4 weeks (total cholesterol 172 +/- 21, LDL cholesterol 116 +/- 8, Lp(a) 26 +/- 8) and after 12 weeks (total cholesterol 169 +/- 20, LDL cholesterol 115 +/- 6, Lp(a) 25 +/- 8) of treatment, returning to basal values on withdrawal of the drug. CONCLUSIONS: Fosinopril is a useful drug for the treatment of the mild to moderate arterial hypertension of heart transplant recipients, in addition to being capable of reducing the serum levels of total cholesterol, LDL cholesterol, and Lp(a). It should therefore be considered a first-line antihypertensive agent with beneficial effects on the lipid profile.
L Almenar; A Osa; M Palencia; A Flores; E Sánchez
Related Documents :
20145357 - Insulin resistance and prevalence of prehypertension and hypertension among community-d...
3985037 - Abnormal retinal artery responses to stress in patients with type i diabetes.
2384067 - Lack of effect of drinking water barium on cardiovascular risk factors.
2057467 - Risk factor changes after cessation of intervention in the multiple risk factor interve...
24296597 - Negative-pressure wound therapy and external fixation device: a simple way to seal the ...
11353577 - The role of the nervous system in hypertension.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation     Volume:  16     ISSN:  1053-2498     ISO Abbreviation:  J. Heart Lung Transplant.     Publication Date:  1997 Apr 
Date Detail:
Created Date:  1997-08-12     Completed Date:  1997-08-12     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9102703     Medline TA:  J Heart Lung Transplant     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  454-9     Citation Subset:  IM    
Cardiology Service, Hospital Universitario La Fe, Servicio Valenciano de Salud, Valencia, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*,  adverse effects
Blood Pressure / drug effects*,  physiology
Cholesterol / blood
Dose-Response Relationship, Drug
Drug Administration Schedule
Follow-Up Studies
Fosinopril / administration & dosage*,  adverse effects
Heart Transplantation / physiology*
Hypertension / drug therapy,  physiopathology
Lipids / blood*
Lipoprotein(a) / blood
Middle Aged
Postoperative Complications / drug therapy,  physiopathology
Treatment Outcome
Triglycerides / blood
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Lipids; 0/Lipoprotein(a); 0/Triglycerides; 57-88-5/Cholesterol; 98048-97-6/Fosinopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Delayed reversal of impaired metabolic vasodilation in patients with end-stage heart failure during ...
Next Document:  Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referr...